Print this page
-
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL).
Protocol: 112512Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
A digital skin cancer prevention intervention for adolescents and their parents
Protocol: 132501Principal Investigator:
- Carolyn J Heckman
Applicable Disease Sites: -
Developing a Single-Session Intervention to Support Adolescent Siblings of Children with Cancer
Protocol: 132408Principal Investigator:
- Christina Amaro
Applicable Disease Sites: -
A digital skin cancer prevention intervention for adolescents and their parents
Protocol: 132501Principal Investigator:
- Carolyn J Heckman
Applicable Disease Sites: